Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: nAMD Clear all
Completed No phase listed Observational

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

NCT06178770
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 26, 2026, 4:32 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05859776
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
50 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1
Drug
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 26, 2026, 4:32 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

NCT06470373
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
Drug
Lead sponsor
Rophibio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jun 26, 2026, 4:32 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
Faricimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Santa Ana, California • Orlando, Florida • Winter Haven, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Not yet recruiting Phase 3 Interventional

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

NCT07516132
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
OTX-TKI
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

NCT06223958
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI (axitinib implant), Aflibercept
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
97
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

NCT03066258
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AKST4290, Placebo, Aflibercept
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
63
States / cities
Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 26, 2026, 4:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

NCT03954626
View directory record Official record
Conditions
Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
brolucuzumab 6 mg IVT
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Phoenix, Arizona • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 26, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

NCT07630649
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Interventions
Ixo-vec
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Deerfield Beach, Florida • Fort Lauderdale, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
KHK4951, Aflibercept Injection
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Completed No phase listed Observational

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

NCT04989699
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI/Sham, Aflibercept/Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Jun 26, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

NCT07614776
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, nAMD
Interventions
ABP 938 8 mg, Aflibercept (US) 8 mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Long Beach, California • Pasadena, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 26, 2026, 4:32 AM EDT
Active, not recruiting Phase 1 Interventional

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

NCT05698329
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions
AIV007
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
21 Years to 90 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jun 26, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jun 26, 2026, 4:32 AM EDT